INBS completes interference study; on track for 510(k) submission in H2 2026

INTELLIGENT BIO SOLUTIONS INC.

Completed Interference Study for fingerprint drug screening system, testing common substances (hand creams, alcohol, oils, dirt, water) for impact on codeine detection.
Study conducted with CenExel Clinical Research, following FDA guidance and ICH GCP guidelines; data analysis underway with LC-MS/MS verification.
Company remains on track to submit FDA 510(k) package in calendar H2 2026 for U.S. market clearance for opiate codeine detection.
Part of comprehensive program including Cut-off Study, Method Comparison Study, precision and penetration testing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.